Raytheon Company (NYSE:RTN) recorded a trading volume of 1.02 million shares, below its 90-day volume average of 1.28 million shares. The stock kicked off the session at $183.65 and later approached $182.85 with a change of -0.77%.Raytheon Company (RTN) Analyst Opinion
Raytheon Company has a consensus outperform rating from 20 Wall Street analysts, and the number of shares currently sold short amount to at least 0.97% of shares outstanding. The stock sank -2.19% last month and is up 28.77 this year. Wall Street is only getting more bullish on the stock, with 18 of analysts who cover RTN having a buy-equivalent rating. Analysts have placed a $202.61 price target on Raytheon Company, suggesting a 10.81% gain from recent close. It’s currently trading about -3.89% below its 52-week high.
Raytheon Company (RTN) surprised the stock market in its last reported earnings when it earned $1.97 a piece versus the consensus-estimated $1.91. Its revenue totaled $6.33 billion up 0.78% from the previous quarter.Raytheon Company (NYSE:RTN) Intraday View
This stock (RTN) is ahead of its 52-week low with 32.79%. Its last month’s stock price volatility remained 0.81% which for the week stands at 1.38%. The share price has moved backward from its 20 days moving average, trading at a distance of -0.94% and stays -1.24% away from its 50 days moving average. Over the last five days, shares have faced -1.06% losses and now is up 9.12% since hitting its 200-day moving average of $173.73. Raytheon Company (RTN) has made its way to a 12-month gain of 26.14%.
Turning to Cymabay Therapeutics, Inc. (NASDAQ:CBAY), its shares were trading at $8.66 a gain of $0.14, on the trading floor. The stock, after opening at $8.51, touched a high of $8.74 before paring much of its gains. So far, analysts are sticking with their bullish recommendations with the consensus call at 1.7. Cymabay Therapeutics, Inc. has 2 buy ratings, 0 holds and 0 sells even after the stock tumbled -7.87% from its high of $9.40 to a $355.93 million market value through last close.
The company’s consensus rating on Reuter’s scale slipped from 1.71 to 1.67 during a month. Analysts set a 12-month price target of $13.83 a share. The target implies a 59.7% spike from where the shares are currently trading. Also, the current price highlights a discount of 84.76% to analysts’ high consensus price target.Cymabay Therapeutics, Inc. (NASDAQ:CBAY) Intraday Trading
The counter witnessed a trading volume of 0.48 million shares versus an average volume of 0.76 million shares during last trading session. Its last month’s stock price volatility remained 6.35% which for the week approaches 5.76%. The lowest price the stock reached in the last trading day was $8.4 and compares with the $1.46 52-week low. The stock recovered 493.15% since its low point and has performed 400.58% year-to-date.